eBulletin Newsletter
NCCN Flash Updates: NCCN Templates® Updated for Malignant Pleural Mesothelioma and NCCN Guidelines® and NCCN Compendium® Updated for Central Nervous System Cancers
NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates®) for Malignant Pleural Mesothelioma to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Malignant Pleural Mesothelioma Version 1.2020.
- Changes to the Chemotherapy Regimen section have been made to the following templates:
- MPM7: PEMEtrexed/CISplatin + Bevacizumab followed by Bevacizumab Maintenance
- MPM8: PEMEtrexed/CARBOplatin + Bevacizumab followed by Bevacizumab Maintenance
- References have been updated on the following template:
- MPM10: Nivolumab
- The following note has been updated in the Monitoring and Hold Parameters section:
- An increased risk of deep venous thrombosis or pulmonary embolism may occur with therapy. Patients should be monitored for signs and symptoms of thromboembolism. Thromboembolic prophylaxis could be considered when clinically warranted. Review drug package insert for risk assessment, monitoring, and prophylaxis recommendations.
- Affected templates:
- MPM7: PEMEtrexed/CISplatin + Bevacizumab followed by Bevacizumab Maintenance
- MPM8: PEMEtrexed/CARBOplatin + Bevacizumab followed by Bevacizumab Maintenance
- Affected templates:
- An increased risk of deep venous thrombosis or pulmonary embolism may occur with therapy. Patients should be monitored for signs and symptoms of thromboembolism. Thromboembolic prophylaxis could be considered when clinically warranted. Review drug package insert for risk assessment, monitoring, and prophylaxis recommendations.
- Drug information notes for the following agent have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
- Bevacizumab
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs and Biologics Compendium (NCCN Compendium®) for Central Nervous System Cancers. These NCCN Guidelines® are currently available as Version 2.2020.
- Principles of Brain and Spinal Cord Tumor Systemic Therapy (BRAIN-D)
- Brain Metastases
- Breast Cancer/HER2-positive
- Tucatinib + trastuzumab + capecitabine (if previously treated with 1 or more anti-HER2-based regimens) has been added.
- The following reference is new: Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.
- Breast Cancer/HER2-positive
- Brain Metastases
Previous updates to the NCCN Guidelines for Central Nervous System Cancers can be found in the UPDATES section of the current version.
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps..